Evidence map›Paper›PMID 39944763›Full record

ArticleACS catalysis2025

Practical Synthesis of Chiral Ferrocenenylphosphino-Gold(I) Catalysts and NEST Analysis of the Enantioinduction.

Pablo Mora, Imma Escofet, Maria Besora, Federica Cester Bonati, Antonio M Echavarren

Abstract read
In one paragraph

Article in ACS catalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pablo MoraBarcelona Institute of Science and Technology, Institute of Chemical Research of Catalonia (ICIQ-CERCA), Av. Països Catalans 16, 43007 Tarragona, Spain.
Imma EscofetBarcelona Institute of Science and Technology, Institute of Chemical Research of Catalonia (ICIQ-CERCA), Av. Països Catalans 16, 43007 Tarragona, Spain.ORCID https://orcid.org/0000-0002-1790-4255
Maria BesoraDepartment de Química Física i Inorgànica, Universitat Rovira i Virgili, C/Marcel·li Domingo s/n, 43007 Tarragona ,Spain.ORCID https://orcid.org/0000-0002-6656-5827
Federica Cester BonatiBarcelona Institute of Science and Technology, Institute of Chemical Research of Catalonia (ICIQ-CERCA), Av. Països Catalans 16, 43007 Tarragona, Spain.
Antonio M EchavarrenBarcelona Institute of Science and Technology, Institute of Chemical Research of Catalonia (ICIQ-CERCA), Av. Països Catalans 16, 43007 Tarragona, Spain.ORCID https://orcid.org/0000-0001-6808-3007

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The concise modular synthesis of a family of monodentate 1,2-disubstituted ferrocene ligands containing a diaryl phosphine and a 2-aryl indole is described. Their gold(I) complexes were applied to the enantioselective gold(I)-catalyzed formal [4 + 2] cycloaddition of 1,6-arylenynes, the enyne cyclization/nucleophile addition of N-tethered 1,6-enynes, and the methoxycyclization of 1,6-arylenynes with high levels of enantioselectivity in all cases. Crystallographic and computational studies highlighted the relevant role of noncovalent interactions within the ligand scaffold and between the ligand and substrate in the modes of enantioinduction in the cyclization of unsaturated substrates. Our recently developed open-source tool NEST was applied to analyze the chiral pockets of the catalysts, which in combination with RDKit allowed us to understand the enantioselectivity in these reactions, paving the way for a predictive-based approach toward the rational development of chiral ligands for enantioselective Au(I) catalysis.

Identifiers

PMID39944763
PMCPMC11812006

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.